citalopram has been researched along with Hyperphagia in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Hyperphagia: Ingestion of a greater than optimal quantity of food.
Excerpt | Relevance | Reference |
---|---|---|
"Escitalopram was started at 10 mg/d with a dosage increase to 20 mg/d after 4 weeks; placebo dosing was identical." | 2.77 | Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. ( Gadde, KM; Gang, CH; Griffing, GT; Vander Wal, JS, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allison, KC | 1 |
Studt, SK | 1 |
Berkowitz, RI | 1 |
Hesson, LA | 1 |
Moore, RH | 1 |
Dubroff, JG | 1 |
Newberg, A | 1 |
Stunkard, AJ | 1 |
Vander Wal, JS | 1 |
Gang, CH | 1 |
Griffing, GT | 1 |
Gadde, KM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Brain Imaging and Treatment Studies of the Night Eating Syndrome[NCT01401595] | Phase 3 | 87 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
Escitalopram Treatment of Night Eating Syndrome: a Randomized Controlled Trial[NCT00636649] | 40 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Outcome of treatment will be measured by self report questionnaire, the Night Eating Symptom Scale ( higher score indicates worse symptoms). The percentage of calories consumed after dinner was estimated by recall at each treatment visit, as compared to their baseline % of intake after dinner, which was calculated through food diaries. The number of nocturnal ingestions (waking during the night and eating) per week was also recalled at each treatment visit. (NCT01401595)
Timeframe: 12 weeks
Intervention | percentage of calories after dinner (Mean) | |
---|---|---|
baseline %calories consumed after dinner | treatment end %calories after dinner | |
Controls | 11.8 | NA |
Night Eating Syndrome Open Label Escitalopram Treatment | 46.1 | 17.4 |
"The responses on the Night Eating Symptom Scale (NESS) will be examined over time.~Subjects will complete the NESS at their baseline visit, and at every treatment visit thereafter. The Night Eating Symptom Scale-II (NESS-II) (Lundgren, Allison, Vinai, & Gluck, 2012) is a 14-item questionnaire (possible range of 0-56, with higher scores indicating more severe symptoms) that assesses the presence of NES features over the course of the previous week. The NESS will indicate whether or not escitalopram is having an effect on our participants' night eating symptoms." (NCT01401595)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline Night Eating Symptom Scale | treatment end night eating symptom scale | |
Controls | NA | NA |
Night Eating Syndrome Open Label Escitalopram Treatment | 30.2 | 15.2 |
Number of nocturnal ingestions (waking and having something to eat) were reported at each visit. (NCT01401595)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
baseline nocturnal ingestions/week | treatment end nocturnal ingestions/week | |
Controls | 0.0 | NA |
Night Eating Syndrome Open Label Escitalopram Treatment | 5.8 | 1.2 |
The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety. Scores range from 0 to 63, with higher scores indicative of higher levels of anxiety. (NCT00636649)
Timeframe: Baseline, 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | -1.5 |
Placebo | -1.8 |
The BDI-II is a 21-item self-report questionnaire designed to measure cognitive, somatic, and behavioral aspects of depression. Scores range from 0 to 63, with higher scores indicating a higher level of depressive symptoms. (NCT00636649)
Timeframe: Baseline, 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | -2.4 |
Placebo | -3.5 |
(NCT00636649)
Timeframe: Baseline, 12 Week
Intervention | mg/dL (Mean) |
---|---|
Escitalopram | 3.9 |
Placebo | 7.6 |
The Perceived Stress Scale (PSS) measures the overall level of stress. This instrument contains 14 items accessing overall appraisals of stress in the past month. Minimum score (best value)=0. Maximum score (worst value)=56. A higher score indicates greater stress. (NCT00636649)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Placebo | -0.55 |
Escitalopram | -2.11 |
(NCT00636649)
Timeframe: Baseline, 12 week
Intervention | kg (Mean) |
---|---|
Escitalopram | -0.43 |
Placebo | 1.12 |
The Night Eating Questionnaire (NEQ) is a 14-item self-report scale designed to assess the symptoms of NES including nocturnal ingestions, evening hyperphagia, morning anorexia, and mood/sleep. Scores range from 0-56, with higher scores indicative of greater severity. The NEQ has an acceptable internal consistency reliability (.70). A cut-score of 25 has been shown to yield a positive predictive value of .62. (NCT00636649)
Timeframe: baseline, 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | -13.0 |
Placebo | -10.6 |
The Night Eating Questionnaire (NEQ) is a 14 item self-report scale designed to assess the symptoms of NES including nocturnal ingestions, evening hypcrphagia, morning anorexia, and mood/slccp. Scores range from 0 to 56, with higher scores indicative of greater severity. (NCT00636649)
Timeframe: Week 12
Intervention | participants (Number) |
---|---|
Escitalopram | 7 |
Placebo | 6 |
The Night Eating Syndrome History and Inventory (NESHI) is an unpublished, semistructured interview used to confirm a diagnosis of NES. It assesses a typical 24-hour food intake, including a recall of all meals and snacks, and sleeping patterns. Based on the recall of all meals and snacks, the interviewer judged whether ≥25% of the daily caloric intake was eaten after the evening meal and how often nocturnal ingestions occurred. The NEQ items were reviewed and informed by the dietary recall during the interview, and a new total score was tallied. A final score of ≥25 for the NEQ items, as reviewed during the NESHI, was used as the criterion for NES. (NCT00636649)
Timeframe: Week 12
Intervention | participants (Number) |
---|---|
Escitalopram | 16 |
Placebo | 12 |
The CGI-I scale is a clinician rating of overall therapeutic effect ranging from 1 (very much improved) to 7 (very much worse) since commencing treatment. (NCT00636649)
Timeframe: 12 weeks
Intervention | participants (Number) |
---|---|
Escitalopram | 12 |
Placebo | 7 |
TASK = task-oriented coping; EMOT = emotion-oriented coping; AVD = avoidance-focused coping; Avoidance-focused coping may be divided into two subtypes: DIS = distraction-oriented coping; SOC = social diversion-oriented coping. CISS is a 48 item self-report measure used to measure responses to stressful situations rated for frequency on a 5 point Likert scales ranging from1, not at all to 5, very much. This measure assesses three coping styles: Task-Oriented, Emotion-Oriented, and two types of Avoidance-Oriented coping (Social Diversion and Distraction). There are 16 items on each of the primary scales (task, emotion, avoidance) and 5 on social diversion and 8 on distraction. Scores are summed for each subscale and then converted to gender-corrected t-scores with a mean of 50 and a standard deviation of 10. T-scores on the CISS range from a low of 25 (1st percentile) to 75 (99th percentile). Higher scores indicate more adaptive levels of coping. (NCT00636649)
Timeframe: Baseline, 12 weeks
Intervention | t-scores (Mean) | ||||
---|---|---|---|---|---|
CISS-TASK | CISS-EMOT | CISS-AVD | CISS-DIS | CISS-SOC | |
Escitalopram | 1.75 | -1.45 | 2.60 | 1.95 | 2.15 |
Placebo | 2.35 | 1.25 | 0 | 3.40 | -2.45 |
(NCT00636649)
Timeframe: Baseline,12 weeks
Intervention | mg/dL (Mean) | |||
---|---|---|---|---|
HDL | LDL | Triglycerides | total cholesterol | |
Escitalopram | -2.8 | -3.9 | 27.5 | -4.5 |
Placebo | -2.2 | 2.8 | -14.0 | -2.3 |
"The TFEQ (also known as the Eating Inventory) measures dimensions of eating behavior including cognitive restraint of eating, disinhibition, and hunger using a combination of dichotomous questions, 4-point likert scales, and one 5-point likert scale. Restraint is comprised of the responses to 21 questions with possible scores ranging from 0 to 21 (Low scores for all scales indicate an uninhibited eating behavior.). Disinhibition is comprised of the responses to 16 questions with possible scores ranging from 0 to 16 (High scores indicate an uninhibited eating behavior strongly depending on external cues). Hunger is comprised of the responses to 14 questions with possible scores ranging from 0 to 14 ( Low scores indicate an eating behavior strongly depending on feelings of hunger.).~RES = Restraint Subscale; DIS = Disinhibition Subscale; HUN = Hunger Subscale" (NCT00636649)
Timeframe: Baseline, 12 weeks
Intervention | units on a scale (Mean) | ||
---|---|---|---|
TFEQ-RES | TFEQ-DIS | TFEQ-HUN | |
Escitalopram | 1.85 | -1.50 | -1.75 |
Placebo | 2.95 | -0.85 | -1.60 |
1 trial available for citalopram and Hyperphagia
Article | Year |
---|---|
Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial.
Topics: Academic Medical Centers; Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Citalopr | 2012 |
1 other study available for citalopram and Hyperphagia
Article | Year |
---|---|
An open-label efficacy trial of escitalopram for night eating syndrome.
Topics: Adult; Chronobiology Disorders; Citalopram; Feeding and Eating Disorders; Female; Humans; Hyperphagi | 2013 |